Summary
Effective July 1, 2025, BCBSWY is removing Humira from all formularies and replacing it with preferred adalimumab biosimilars (Hadlima, Simlandi, adalimumab-aaty, adalimumab-adaz). Additionally, all Wyoming Educators' Benefit Trust (WEBT) members will transition to Wyoming Total Choice network with new ID cards showing 'PPO' indicator and 'YWY' prefix.
Get alerts when payers change rules like this one
We check Blue Cross Blue Shield of Wyoming and other payers every day and email you when a change matches your specialty and state.
Get Blue Cross Blue Shield of Wyoming alertsPolicy Monitoring is free. No card required.
What to do
Action · 4 steps
01Before July 1, 2025: Billing team must identify all Humira patients and coordinate with providers to transition prescriptions to preferred biosimilars (Hadlima, Simlandi, adalimumab-aaty, adalimumab-adaz).
02Update patient records to reflect formulary changes and inform patients about copay assistance availability.
03For WEBT members: Update billing system to recognize new 'YWY' member ID prefix and verify 'PPO' network indicator on new ID cards.
04Check all patient insurance cards during visits to ensure accurate identification and prevent claim denials.
Original notice
BCBSWY Humira Update
bcbswy.com · Always check the source before changing claims.